Biosimilars accounted for 15% of the Valencian market in 2015. “They are now almost double, around 27%” said Patricia Lacruz, leading to €900,000 in savings, ” in addition to promoting competition and that branded biologicals have had to reduce their prices”.
Valencia has 3 core pillars for its pharmaceutical policies:
- promotion of biosimilar drugs
- central purchasing
- replacement algorithms for prescriptions
These policies help improve efficiency and cut costs.